Total Payments
$10,387
2024 Payments
$1,848
Companies
37
Transactions
646
Medicare Patients
2,101
Medicare Billing
$512,176
Payment Breakdown by Category
Food & Beverage$10,194 (98.1%)
Education$193.47 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,194 | 641 | 98.1% |
| Education | $193.47 | 5 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,936 | 107 | $0 (2024) |
| ABBVIE INC. | $1,096 | 65 | $0 (2024) |
| Janssen Biotech, Inc. | $1,074 | 100 | $0 (2024) |
| UCB, Inc. | $987.03 | 54 | $0 (2024) |
| PFIZER INC. | $825.74 | 69 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $573.10 | 32 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $478.29 | 25 | $0 (2024) |
| Lilly USA, LLC | $445.32 | 29 | $0 (2024) |
| Genentech USA, Inc. | $337.47 | 21 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $225.31 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,848 | 94 | Amgen Inc. ($350.47) |
| 2023 | $1,852 | 90 | Amgen Inc. ($386.03) |
| 2022 | $1,299 | 72 | Amgen Inc. ($312.65) |
| 2021 | $369.01 | 24 | Amgen Inc. ($118.97) |
| 2020 | $397.72 | 23 | Amgen Inc. ($95.37) |
| 2019 | $1,483 | 92 | AbbVie, Inc. ($273.91) |
| 2018 | $1,747 | 132 | PFIZER INC. ($244.73) |
| 2017 | $1,392 | 119 | Amgen Inc. ($270.15) |
All Payment Transactions
646 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $22.39 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: Rare Disease | ||||||
| 12/11/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $30.86 | General |
| Category: Cardiology | ||||||
| 12/10/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $4.52 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: Inflammation | ||||||
| 12/04/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.44 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/20/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Immunology | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $29.11 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.73 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: Dermatology | ||||||
| 10/31/2024 | Organon Llc | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 10/30/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: Immunology | ||||||
| 10/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.33 | General |
| Category: IMMUNOLOGY | ||||||
| 10/17/2024 | SCILEX PHARMACEUTICALS INC. | GLOPERBA (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Analgesic | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: Immunology | ||||||
| 10/15/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $8.38 | General |
| Category: Inflammation | ||||||
| 10/10/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Rheumatology | ||||||
| 10/09/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Rare Disease | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $32.28 | General |
| Category: Dermatology | ||||||
| 10/02/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $30.78 | General |
| Category: Immunology | ||||||
| 09/26/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 440 | 2,686 | $217,460 | $93,369 |
| 2022 | 9 | 487 | 2,818 | $192,137 | $87,787 |
| 2021 | 10 | 495 | 2,968 | $203,955 | $99,653 |
| 2020 | 12 | 679 | 11,292 | $473,684 | $231,367 |
Total Patients
2,101
Total Services
19,764
Medicare Billing
$512,176
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 236 | 439 | $85,180 | $37,001 | 43.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 1,680 | $57,000 | $29,936 | 52.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 23 | 118 | $31,742 | $11,464 | 36.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $18,975 | $7,989 | 42.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 35 | 238 | $8,330 | $2,552 | 30.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 97 | $6,693 | $2,047 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 26 | $3,650 | $1,731 | 47.4% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 19 | 19 | $5,890 | $649.62 | 11.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 16 | 1,680 | $41,280 | $27,738 | 67.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 180 | 309 | $58,710 | $24,595 | 41.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 25 | 129 | $34,701 | $13,111 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 142 | 183 | $24,705 | $11,448 | 46.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 52 | 52 | $14,300 | $5,886 | 41.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 15 | 112 | $7,728 | $2,391 | 30.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 29 | 206 | $7,210 | $2,283 | 31.7% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 15 | 65 | $715.00 | $292.23 | 40.9% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2022 | 13 | 82 | $2,788 | $42.89 | 1.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 242 | 484 | $85,940 | $42,020 | 48.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 19 | 1,800 | $39,600 | $28,575 | 72.2% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 25 | 118 | $31,742 | $13,014 | 41.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 62 | 62 | $17,050 | $6,603 | 38.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 60 | 77 | $9,862 | $4,749 | 48.2% |
| 96415 | Infusion of chemotherapy into a vein | Office | 2021 | 14 | 91 | $6,279 | $2,042 | 32.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 32 | 172 | $6,020 | $1,890 | 31.4% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Office | 2021 | 12 | 12 | $3,720 | $443.64 | 11.9% |
About Dr. Jill Mcclory, M.D
Dr. Jill Mcclory, M.D is a Rheumatology healthcare provider based in Hickory, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922190255.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jill Mcclory, M.D has received a total of $10,387 in payments from pharmaceutical and medical device companies, with $1,848 received in 2024. These payments were reported across 646 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($10,194).
As a Medicare-enrolled provider, Mcclory has provided services to 2,101 Medicare beneficiaries, totaling 19,764 services with total Medicare billing of $512,176. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Hickory, NC
- Active Since 09/28/2006
- Last Updated 10/12/2016
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1922190255
Products in Payments
- Enbrel (Biological) $1,560
- Cimzia (Drug) $940.67
- ORENCIA (Biological) $573.10
- XELJANZ (Drug) $544.38
- TREMFYA (Drug) $506.58
- RINVOQ (Biological) $439.59
- SIMPONI ARIA (Biological) $398.08
- Humira (Biological) $339.23
- ACTHAR (Biological) $334.09
- TALTZ (Drug) $322.88
- COSENTYX (Drug) $270.04
- Rituxan (Biological) $251.30
- SAPHNELO (Biological) $225.31
- KEVZARA (Biological) $209.35
- COSENTYX (Biological) $208.25
- LYRICA (Drug) $185.33
- KRYSTEXXA (Biological) $176.85
- BENLYSTA (Biological) $154.71
- SKYRIZI (Biological) $151.79
- KEVZARA SARILUMAB INJECTION (Biological) $137.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.